Skip to main content

Table 2 Approved indications for kinase-targeted therapies

From: Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia

Disease

Kinase target

Approved inhibitors

Chronic myeloid leukemia (CML)

BCR-ABL1

Imatinib, dasatinib, nilotinib, bosutinib, ponatinib

Ph acute lymphocytic leukemia (ALL)

BCR-ABL1

Imatinib, dasatinib, nilotinib, bosutinib, ponatinib

Mastocytosis

KIT

Imatinib

Hypereosinophilic syndrome (HES)

FIP1L1-PDGFRα

Imatinib

Chronic eosinophilic leukemia (CEL)

FIP1L1-PDGFRα

Imatinib

PDGFRβ

Imatinib

Gastrointestinal stromal tumors (GIST)

KIT; PDGFRα

Imatinib

Melanoma

BRAF

Vemurafenib

Non-small cell lung cancer (NSCLC)

EGFR1

Gefinitinib, erlotinib

ALK

Crizotinib, ceritinib

Chronic lymphocytic leukemia (CLL)

BTK

Ibrutinib

Mantle cell lymphoma

BTK

Ibrutinib

  1. BCR, breakpoint cluster region; ABL1, Abelson murine leukemia viral oncogene homolog 1; KIT, c-kit proto-oncogene; FIP1L1, FIP1-like 1; PDGFRa, platelet-derived growth factor receptor alpha; PDGFRb, platelet-derived growth factor receptor beta; BRAF, B-Raf proto-oncogene; EGFR1, epidermal growth factor receptor 1; ALK, anaplastic lymphoma kinase; BTK, Bruton's tyrosine kinase.